Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Benzinga · 2d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.